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Summary 
Biological function of the BCR-ABL oncogene is de- 
pendent on its activated tyrosine kinase. Mutations 
that inactivate the SRC homology 2 (SH2) domain, the 
GRB2-binding site in BCR, or the major autophosphor- 
ylation site of the kinase domain selectively disrupt 
downstream signaling but not tyrosine kinase activity. 
Despite a loss of fibroblast transformation activity, all 
three mutants retain the ability to render hematopoi- 
etic cell lines growth factor independent and transform 
primary bone marrow cells in vitro. In vivo tests of 
malignant potential reveal a most critical role for sig- 
nals dependent on the BCR-ABL SH2 domain. The effi- 
ciency of both fibroblast and hematopoietic transfor- 
mation by BCR-ABL is strongly affected by increased 
dosage of the SHC adapter protein, which can connect 
tyrosine kinase signals to RAS. The BCR-ABL onco- 
gene activates multiple alternative pathways to RAS 
for hematopoietic transformation. 
Introduction 
Deregulated RAS signaling is associated with a wide vari- 
ety of human leukemia (Janssen et al., 1987; Sawyers 
and Denny, 1994). The mechanisms of RAS activation 
in leukemia include the following: RAS point mutations, 
inactivating mutations of RAS-GAP molecules, or the sig- 
nals from tyrosine kinase oncogenes (reviewed by Saw- 
yers and Denny, 1994). Multiple SH2 domain-containing 
adapter molecules can connect tyrosine kinase signals to 
the RAS signaling pathway (reviewed by Pawson, 1994). 
BCR-ABL is a chimeric tyrosine kinase oncogene (re- 
viewed by Kurzrock et al., 1988) generated by the recipro- 
cal t(9;22) (q34;q11) translocation that fuses BCR gene 
sequence upstream of the second exon of the c-ABL gene 
(Kurzrock et al., 1988). Two BCR-ABL proteins, P210 and 
P185, are associated with chronic myelogenous leukemia 
(CML) and acute lymphocytic leukemia (ALL), respec- 
tively. BCR-ABL can transform fibroblast and hematopoi- 
etic cells in vitro (Lugo et al., 1990; McLaughlin et al., 
1989). P210 or P185 can recapitulate a CML-like disease 
in mice (Daley et al., 1990; Elefanty et al., 1990; Kelliher 
et al., 1990; Gishizky et al., 1993). BCR-ABL provides 
the initiating event, but additional genetic changes are 
required for the full malignant phenotype (Kurzrock et al., 
1988; McLaughtin et al., 1989). 
The tyrosine kinase activity of the BCR-ABL molecule 
is one essential determinant of its transforming potency 
(Lugo et al., 1990; McLaughlin et al., 1989). Mutations that 
inactivate tyrosine kinase activity block transformation for 
multiple ABL alleles (reviewed by Rosenberg and Witte, 
1988). Higher BCR-ABL tyrosine kinase dosage corre- 
lates with a quantitative increase in transforming potency 
in multiple assays (Lugo et al., 1990; McLaughlin et al., 
1989). 
The connection between the BCR-ABL tyrosine kinase 
signal and downstream signal transduction pathways is 
provided by multiple functional domains (Muller et al., 
1991; McWhirter and Wang, 1991; Pendergast et al., 
1993a, 1993b; Afar et al., 1994). Mutations of a major auto- 
phosphorylation site (Y793F) within the catalytic domain 
(Pendergast et al., 1993a; Afar et al., 1994), the GRB2- 
binding site (Y177F) within BCR (Pendergast et al., 1993b; 
Pull et al., 1994), or the SH2 domain (R552L) (Afar et al., 
1994) block the ability of BCR-ABL to stimulate growth 
of rodent fibroblast cells in soft agar without significantly 
altering the activity of the kinase. Autophosphorylated 
Y793 of P185 BCR-ABL may provide a docking site for 
SH2-containing cellular proteins (Pendergast et al., 1993a; 
Afar et al., 1994). Mutation of the arginine residue within 
the conserved FLVRES motif of the ABL SH2 domain 
(R552L) blocks binding to phosphotyrosine-containing pro- 
teins (Mayer et al., 1992). Mutation of Y177 blocks the 
direct interaction between the GRB2 adapter molecule 
and BCR-ABL (Pendergast et al., 1993b; Pull et al., 1994). 
This mutation has previously been reported to impair 
BCR-ABL activation of the RAS signal transduction path- 
way in fibroblast cells and to block hematopoietic cell 
transformation (Pendergast et al., 1993b). 
We now demonstrate that BCR-ABL activates multiple 
signaling pathways to RAS in hematopoietic ells. A BCR- 
ABL mutant hat is unable to bind the GRB2 adapter mole- 
cule retains the ability to transform hematopietic ells in 
vitro and full malignant potential in vivo. Activation of the 
SHC adapter provides an alternative signal from BCR- 
ABL to RAS in hematopoietic ells. Increased SHC dosage 
can complement both fibroblast and hematopoietic trans- 
formation by BCR-ABL. 
Results 
BCR-ABL Mutants Blocked for Fibroblast 
Transformation Cause Factor-lmdependent 
Growth of Myeloid and Lymphoid Cell Lines 
Point mutations of BCR-ABL were constructed that un- 
couple signaling to downstream pathways, but leave the 
BCR-ABL catalytic activity intact. Mutations of an auto- 
phosphorylation site (Y793F) within the kinase domain, of 
an autophosphorylation site (Y177F) within BCR, and of 
the SH2 domain (R552L) have all been shown to block 
BCR-ABL transformation of rodent fibroblast cells (Afar 
et al., 1994; Pendergast et al., 1993a, 1993b). Combina- 
tions of double- and triple-point mutations were also gener- 
Cell 
982 
A 
NH2 BCR SH3SH2 SH1 COOH 
P18s wr m====== I I_ I I 
P18s,~93FSH1 ~ 1  F '~E I 
F R 
PleSRSS2LSH2 ~ l'l'l~ I I 
y L 
PlSSY177F GRB2 ~ I I t 
2o~-  ~MIM-, ~ ~--BCa-ABL 
116 - -  
¢-ABL E~LOT 
~- -  BCR-ABL 
i 
c~-P-TYR BLOT 
~lp lU l l  ~ gB~,o ~ , ,~-- p62 
c~-P-TYR BLOT 
Figure 1. Expression of BCR-ABL Point Mutants in Rat1 Fibroblast 
Cells 
(A) Diagram of point mutations generated inthe P185 BCR-ABL gene. 
Rat1 fibroblast cells were infected with recombinant retrovirus encod- 
ing BCR-ABL mutants, and anti-ABL (B) or anti-phosphotyrosine (C 
and D) Western blots were performed. Arrows indicate the position of 
P185 BCR-ABL proteins. The absence of a tyrosine-phosphorylated 
62 kDa cellular protein in cells expressing BCR-ABL molecules with 
an SH2 (R552L) mutation is indicated (D). 
ated within P185 BCR-ABL by site-directed mutagenesis 
(Figure 1A). 
Helper-free retroviral stocks were prepared by transient 
transfection of BCR-ABL plasmids along with the retrovi- 
ral Psi- packaging vector in 293 T cells (Muller et al., 1991 ; 
Pear et al., 1993; Afar et al., 1994). Following infection of 
Rat1 fibroblast cells with recombinant retroviruses, similar 
levels of protein expression for wild type and each of the 
P185 mutants was detected by anti-ABL Western blotting 
(Figure 1 B). Anti-phosphotyrosine Western blots show that 
BCR-ABL mutant-encoded proteins contain similar levels 
of phosphotyrosine as does wild-type BCR-ABL (Figure 
1C). BCR-ABL molecules mutated at the SH2 domain 
(R552L) are tyrosine autophosphorylated in vivo with a 
similar efficiency as other BCR-ABL molecules, but dem- 
onstrate a decrease in the phosphorylation of a prominent 
62 kDa cellular protein band (Figure 1 D; Ellis et al., 1990; 
Afar et al., 1994). 
The ability of tyrosine kinase oncogenes to render hema- 
topoietic ell lines growth factor independent is a measure 
of their ability to activate RAS (Satoh et al., 1991). BCR- 
ABL permits factor-independent growth of a variety of he- 
rnatopoietic ell lines (Daley and Baltimore, 1988; Young 
et al., 1991 ; Pendergast et al., 1993a). Interleukin-7 (IL-7)- 
dependent early B-lymphoid cells (clone H, Young et al:, 
Table 1. Comparison of Factor-Independent Growth of 
Hematopoietic Cells and Fibroblast Transformation by 
BCR-ABL Mutants 
Rat1 Agar Clone H DAGM 
Construct Colonies (IL-7) (GM-CSF) 
Tk NEe 0 0 of 96 0 of 192 
P185 wild type >150 91 of 96 54 of 192 
P185 Y793F SH1 1 73 of 96 92 of 192 
P185 R552L SH2 1 51 of 96 55 of 192 
P185 Y177F G R B2 2 85 of 96 37 of 192 
The ability of clone H or DAGM hematopoietic cells to be rendered 
factor-independent for growth following infection by a variety of BCR- 
ABL retroviruses was determined. Wells were scored positive that 
demonstrated the outgrowth of factor-independent cells after 14 days 
postplating. Rat1 cells were infected using the same retroviral stocks, 
and the average number of macroscopic olonies (>0.75 mM) ob- 
served after 21 days in agar are indicated. 
1991) and granulocyte/macrophage colony-stimulating 
factor (GM-CSF)-dependent myeloid cells (DAGM, Ren- 
nick et al., 1987) were infected with retroviral stocks. At 
2 days postinfection, growth factor was removed from the 
media. Any of the BCR-ABL single-point mutants can 
cause factor-independent growth of DAGM or clone H cells 
with a similar efficiency as wild-type BCR-ABL (Table 1 ; 
Pendergast et al., 1993a). No single mutation inactivates 
a domain that is essential for growth factor independence. 
Hematopoietic Transformation Analysis of BCR-ABL 
Mutants In Vitro and In Vivo 
Fresh murine bone marrow was infected with matched 
retroviral stocks of wild-type and BCR-ABL point mutant- 
encoding retroviruses. Following infection, bone marrow 
cells were plated under conditions that support the growth 
of transformed early B-lymphoid cells (Whitlock and Witte, 
1981). At 21 days following infection, bone marrow cul- 
tures infected with retrovirus encoding the neomycin resis- 
tance gene alone develop an adherent stromal cell layer 
but few nonadherent cells (<1 × 104 cells/ml) (Table 2; 
McLaughlin et al., 1989). BALB/c bone marrow infected 
with retrovirus tocks encoding BCR-ABL wild type or sin- 
gle-point mutants demonstrated an outgrowth of trans- 
formed early B-lymphoid cells (>1 x 106 cells/ml) within 
21 days (Table 2). The efficiency with which the BCR- 
ABL single-point mutants transform bone marrow is 
slightly diminished relative to wild-type BCR-ABL, as dem- 
onstrated by a decrease in the ratio of transformed cul- 
tures (Table 2). Nevertheless, each of the P185 single- 
point mutants can transform pre-B-lymphoid cells in this 
assay. The only discernible difference observed was a 
delay of between 1-3 days for mutant transformed cells 
to reach confluence (>1 x 108 cells/ml). Double- and triple- 
point mutants of BCR-ABL failed to transform bone mar- 
row cells (Table 2). Cells transformed by wild-type BCR- 
ABL and single-point mutants demonstrated similar level 
of BCR-ABL expression and cellular phosphotyrosine- 
containing proteins (data not shown). 
The Y177F GRB2-binding mutant of BCR-ABL was pre- 
viously reported to be unable to transform naive bone mar- 
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Table 2. Bone Marrow Transformation by BCR-ABL Mutants 
Number of Transformed 
Construct Cultures/Total 
Tk NEO O/9 
P185 wild type 9/9 
P185 Y793F SH1 11/15 
P185 R552L SH2 12/15 
P185 Y177F GRB2 15120 
P185 Y793F plus R552L 0/8 
P185 Y793F plus Y177F 0/8 
P185 R552L plus Y177F 0/8 
P185 Triple Mutant 0/8 
Fresh BALB/c bone marrow was infected with BCR-ABL retroviral 
stocks normalized to give equivalent expression following acute infec- 
tion into fibroblast cells. Cultures were scored positive that demon- 
strated >1 x 106 nonadherent cells/ml at 21 days following infection. 
The number of cultures positive over total represents the total from 
at least three separate experiments for each BCR-ABL allele tested. 
None of the double-point mutants nor the triple-point mutant of BCR- 
ABL were capable of giving outgrowths oftransformed B-lymphocytes. 
row using a similar in vitro transformation assay (Pender- 
gast et al., 1993b). However, in our assays, this mutant 
clearly scores positive for bone marrow transformation 
(Figure 2A; Table 2). To exclude the possibility that a rever- 
sion of the GRB2-binding site mutation (Y177F) occurred, 
the association between the GRB2 adaptor molecule and 
BCR-ABL was examined (Figure 2B). When BCR-ABL 
proteins are immunoprecipitated from transformed bone 
marrow cell extracts, GRB2 associates with the wild-type 
BCR-ABL kinase, but not the Y177F mutant (Figure 2B). 
These results clearly demonstrate that a direct interaction 
between BCR-ABL and the GRB2 adaptor molecule is 
not essential for in vitro transformation of murine bone 
marrow. 
The most stringent est of BCR-ABL oncogenic potential 
is the ability to cause leukemia in mice. One strategy is 
to first transform bone marrow cells in vitro, followed by 
injection into mice (Whitlock and Witte, 1981; McLaughlin 
et al., 1989; KeUiher et al., 1991). The advantage of this 
approach is that the observed latency period until leuke- 
mia is shorter (Whitlock and Witte, 1982; McLaughlin et 
al., 1989). 
When ABL transformed B-lymphoid cells are grown in 
culture for greater than 8 weeks, they lose their depen- 
dence on a stromal cell layer for growth and demonstrate 
a higher potency for tumor formation in animals (Whitlock 
and Witte, 1981). BCR-ABL wild-type and point mutant- 
infected transformed bone m arrow cells were passaged in 
culture for more than 20 weeks. There was no discernible 
difference in the ability of bone marrow cells transformed 
by different BCR-ABL alleles to grow in vitro when cultured 
in the absence of a stromal feeder layer. 
To avoid any host immune response, CB-17 scidlscid 
mice served as recipient animals (reviewed by Dick et al., 
1991). BCR-ABL transformed cell lines were injected sub- 
cutaneously (1 x 10 B cells/site) bilaterally into the flanks 
of CB-17 scidlscid mice. Within 10-21 days, the wild-type, 
GRB2-binding site mutant (Y177F), and autophosphoryla- 
tion site mutant (Y793F) transformed bone marrow cells 
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Figure 2, BCR-ABL Bone Marrow Transformation Is ndependent of
GRB2 Binding 
(A) Pictures of bone marrow cultures infected with the indicated retrovi- 
ral stocks. Bone marrow infected with a retrovirue encoding the neomy- 
cin gene (NEO) result in the outgrowth of adherent stromal cells. Bone 
marrow infected with P185 wild-type (WT) or the Y177F mutant encod- 
ing retrovirus results in the outgrowth of nonadherent transformed 
pre-B cells. 
(B) BCR-ABL proteins were immunoprecipitated from transformed 
bone marrow cells using polyclonal antibodies raised against the ABL 
carboxyl terminus. Immunoprecipitates were analyzed by SDS-poly- 
acrylamide gel electrophoresis followed by immunoblotting with anti- 
ABL or anti-GRB2 (Transduction Labs) monoclonal antibodies. The 
P185 Y177F mutant protein does not associate with the GRB2 mole- 
cule in transformed cells. 
gave rise to local tumors at the site of injection (>1 cm 
diameter). Recipient mice developed dramatic spleno- 
megaly and massive lymphadenopathy, with spleen sizes 
typically 5-10 times larger than for control mice. Bone 
marrow cells transformed by wild-type BCR-ABL, the 
GRB2-binding (Y177F) mutant, or the autophosphoryla- 
tion (Y793F) mutant demonstrated an equivalent highly 
malignant phenotype in vivo (Table 3). 
Despite the long-term culture of cells transformed by the 
BCR-ABL SH2 mutant in vitro, there was a dramatically 
reduced malignant phenotype when the cells were intro- 
duced into CB-17 scidlscid mice (Table 3). Cells trans- 
formed by wild-type BCR-ABL rapidly gave rise to tumors 
(10-14 days) bilaterally in all mice injected. In contrast, 
BCR-ABL R552L SH2 mutant-expressing cells caused 
tumors in only two recipient mice, at only a single site of 
injection per mouse. The latency period for tumor forma- 
tion in these two animals was increased to 10-12 weeks 
for BCR-ABL R552L SH2 transformed cells (Table 3). The 
BCR-ABL SH2 mutant ransformed cells are poorly tumor- 
igenic, demonstrating that efficient malignant ransforma- 
tion in vivo requires an intact SH2 domain. 
Redundant Signaling from BCR-ABL to RAS 
Involves the SHC Adapter Molecule 
In the absence of direct GRB2 binding to BCR-ABL, addi- 
tional signals to RAS through SH2 domain-containing 
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Table 3. Malignant Growth of Bone Marrow Cells Transformed by 
BCR-ABL Mutants 
Tumors 
Number of 
Construct Sites/Total Latency (weeks) 
Control 0/8 -- 
P185 wild type 7/7 2 
P185 Y793F SH1 8/8 3 
P185 Y177F GRB2 8/8 2-3 
P185 R552L SH2 2/8 10-12 
Bone marrow cells transformed by various BCR-ABL mutants were 
grown in vitro on bone marrow stroma for 20 weeks and then selected 
for stroma-independent growth in culture. We injected subcutaneously 
1 x 106 cells/site bilaterally into the flanks of CB-17 scidlscid mice. 
Mice injected with cells expressing wild-type BCR-ABL, the GRB2- 
binding mutant )Y177F), or the autophosphorylation site mutant 
(Y793F) developed local tumors at the site of injection within 10-21 
days. Mice that developed tumors were autopsied and shown to have 
metastatic growth of tumor cells in lymph nodes, spleen, and bone 
marrow. Mice injected with cells expressing the BCR-ABL SH2 
(R552L) mutant developed tumors at a lower frequency and after a 
longer latency period. 
adaptor molecules may take place. The SHC and CRK-L 
molecules are likely candidates, since they have been im- 
plicated in RAS activation (Pelicci et al., 1992; Ravichan- 
dran et al., 1995; ten Hoeve et al:, 1994; Nichols et al., 
1994) and become tyrosine phosphorylated in BCR-ABL 
transformed hematopoietic ells. The SHC adapter when 
tyrosine phosphorylated binds the GRB2 molecule and 
stimulates GRB2-SOS complex formation (Ravichandran 
et al., 1995). The amino acid sequence surrounding the 
high affinity GRB2-binding site (Y317) of SHC (Salcini et 
al., 1994) is identical to the GRB2-binding site (Y177) of 
BCR-ABL (Pendergast et al., 1993b; PuU et al., 1994), sug- 
gesting that the two sites might be functionally redundant. 
To demonstrate alternative connections between BCR- 
ABL and RAS activation, we examined SHC phosphoryla- 
tion and SHC-GRB2 complex formation. Cell lysates from 
DAGM cells rendered growth factor independent by differ- 
ent BCR-ABL mutants or the parental DAGM cell line were 
immunoprecipitated with SH C-specific antisera. Anti-SHC 
immunoprecipitates demonstrate that SHC is expressed 
in all of the cell lines at equivalent levels (Figure 3, top). 
SHC is tyrosine phosphorylated in each of the BCR-ABL 
transformed cell lines, including the P185 Y177F GRB2- 
binding mutant, but not in the parental cell lines (Figure 
3, middle). Tyrosine-phosphorylated SHC proteins stably 
associate with the GRB2 adaptor molecule in these cells 
(Figure 3, bottom). The formation of SHC-GRB2 com- 
plexes in BCR-ABL transformed cells occurs without di- 
rect BCR-ABL/GRB2 association. These results demon- 
strate that there are alternate pathways from BCR-ABL 
to RAS activation in hematopoietic ells. 
Increased SHC Dosage Complements BCR-ABL For 
Fibroblast And Hematopoietic Transformation 
To test whether increased expression of the SHC molecule 
can complement he P185 Y177F GRB2 mutant for fibro- 
blast transformation, both genes were introduced simulta- 
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Figure 3. SHC-GRB2 Association in BCR-ABLTransformed Myeloid 
Cells 
Parental DAGM cells or cells rendered growth factor independent by 
different forms of BCR-ABL were analyzed for activation of SHC phos- 
phorylation and association with GRB2. Cell lysates were immunopre- 
cipitated with anti-SHC polyclonal antibodies. Immunoprecipitates 
were analyzed by SDS-polyacrylamide gel electrophoresis followed 
by blotting with anti-SHC monoclonal antibodies (top), anti-phosphoty- 
rosine antibodies (middle), or anti-G RB2 antibodies (bottom). The posi- 
tion of the p52 and p46 forms of SHC and the GRB2 molecules are 
indicated by arrows. As a specificity control, cell extracts from P185 
wild-type (P185 WT) expressing cells were immunoprecipitated with 
normal rabbit serum (NRS). 
neously into Rat1 cells. Retroviral constructs were pre- 
pared that have the control neomycin resistance gene or 
the wild-type human SHC cDNA whose transcription is 
driven bythe retroviral long terminal repeat (LTR) promoter 
(Figure 4). Transcription of different BCR-ABL alleles was 
driven by the thymidylate kinase promoter (Figure 4). 
Retrovirus encoding both SHC and P185 Y177F GRB2 
mutant demonstrate a rescue of the transformed pheno- 
type resulting in nearly 10 times the number of colonies 
and with a larger average colony size as well as increased 
acidification of the medium as compared to the P185 
Y177F GRB2-binding mutant with the control neomycin 
gene (Figure 4). A 5- to 10-fold increase in SHC expression 
over endogenous levels, as monitored by Western blotting 
(data not shown), was not sufficient for soft agar colony 
formation in Rat1 cells (Figure 4). SHC overexpression 
thus supersedes the requirement for an intact GRB2- 
binding site in BCR-ABL. Elevated SHC expression may 
function to increase the dosage of RAS signaling in the 
absence of a direct BCR-ABL/GRB2 interaction. 
Retrovirus encoding both SHC and BCR-ABL were uti- 
lized to infect fresh bone marrow (Figure 5). Transformed 
pre-B-lymphoid cells were counted at 9, 13, and 16 days 
following infection (Figure 5). Retrovirus encoding both 
SHC and the P185 (Y177F) GRB2 mutant demonstrated a
shortened time to confluence (Figure 5A). Wild-type BCR- 
ABL also induced faster growth with increased SHC dos- 
age (Figure 5B). The SHC adapter molecule can synergize 
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Figure 4. Complementation f BCR-ABL Fibroblast Transformation . 
by SHC 
Recombinant retrovirus of the indicated constructs was prepared and 
infected into Rat1 fibroblast cells. At 2 days postinfection, 5 x 104 
cells were plated onto soft agar in 20% serum in duplicate. SHCtkNeo 
and tkNeo constructs represent cells that were selected for 14 days 
in G418 prior to plating in agar to enrich for infected cells. The average 
number of colonies (>0.75 mm) observed after 21 days in agar are 
indicated, Plates demonstrating small <1 mm colonies, large >2 mm 
colonies, or medium-sized colonies are indicated, Acidification of the 
culture medium is indicated. 
with BCR-ABL for hematopoietic transformation and can 
stimulate the rate of transformation by a BCR-ABL GRB2- 
binding mutant. 
Discuss ion  
Genetic and biochemical evidence strongly implicates 
RAS signaling in BCR-ABL transformation (Mandanas et 
al., 1993; ten Hoeve et al., 1994; Pull et al., 1994; Sawyers 
et al., 1995). Dominant negative forms of RAS block BCR- 
ABL transformation of both fibroblast and hematopoietic 
cells (Sawyers et al., 1995). Connections between BCR- 
ABL and RAS signaling are likely, therefore, to be essential 
for transformation. 
The GRB2 molecule constituitively associates with the 
RAS nucleotide xchange factor SOS and has been impli- 
cated in RAS activation (Lowenstein et al., 1992; Skolnik 
et al., 1993; Chardin et al., 1993). A direct interaction be- 
tween the GRB2 adapter molecule and BCR-ABL had 
been previously reported to be essential for BCR-ABL 
activation of the RAS signaling pathway for fibroblast and 
hematopoietic transformation (Pendergast et al., 1993b). 
In direct contrast, we demonstrate that GRB2 binding to 
BCR-ABL via phosphorylated Y177 is not required for the 
RAS-dependent phenomena of growth factor indepen- 
dence, for hematopoietic transformation of bone marrow, 
or for in vivo tumor formation (Figure 2; Tables 2 and 3). 
In concert with our finding, the v-ABL oncogene can effec- 
tively transform hematopoietic cells, yet does not directly 
bind the GRB2 molecule (data not shown). Similarly, the 
recently described translocation product TEL-ABL gener- 
ates an activated tyrosine kinase oncogene that lacks a 
discernible GRB2-binding site (Papadopoulos et al., 
1995). These results all show that signaling to RAS via a 
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Figure 5. Stimulation ofBCR-ABL Hematopoietic Transformation by 
SHC 
Recombinant retrovirus was prepared and normalized for BCR-ABL 
expression as described in the Experimental Procedures. Fresh mu- 
rine bone marrow as infected by the retroviral stocks, and the number 
of nonadherent transformed pre-B lymphocytes was counted on the 
indicated ays following infection. Cell counts represent the number 
of total cells per 6 cm tissue culture plate. The results represent the 
average number of cells from four separate tissue culture plates. 
direct GRB2-binding pathway cannot be a dominant path- 
way for hematopoietic transformation by ABL oncogenes. 
Since activation of RAS is essential for BCR-ABL trans- 
formation, alternate pathways to RAS activation must exist 
in the absence of GRB2 binding. SHC-GRB2 complexes 
are present in hematopoietic ells transformed by the 
BCR-ABL GRB2-binding mutant (Figure 3). Increased 
dosage of the SHC adapter molecule complements the 
P185 Y177F GRB2-binding mutant for fibroblast ransfor- 
mation and stimulates the rate of hematopoietic transfor- 
mation. These results demonstrate that there are multiple 
redundant signaling pathways from BCR-ABL to RAS. 
Blocking any single connection between BCR-ABL and 
RAS is therefore not likely to impair hematopoietic trans- 
formation. 
The best examples of redundancy in signaling to RAS 
are provided by receptor tyrosine kinase molecules. An 
epidermal growth factor receptor mutant lacking all known 
autophosphorylation sites is unable to bind to the GRB2 
molecule, yet can still induce SHC phosphorylation and 
RAS activation in fibroblast cells (Gotoh et al., 1994). Tar- 
geted disruption of the insulin receptor substrate 1 (Irsl) 
gene in mice provides further compelling evidence for re- 
dundancy in signaling to RAS (Tamemoto et al., 1994; 
Araki et ai., 1994). IRS1 is the major substrate of the insulin 
receptor and can bind to a number of SH2-containing 
adapter molecules, including GRB2. Mice lacking IRS1 
demonstrate no morphological abnormalities (Tamemoto 
et al., 1994; Araki et al., 1994). Insulin stimulation of liver 
cells from these mice results in SHC tyrosine phosphoryla- 
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tion and act ivat ion of  the RAS-MAP k inase pathway (Ta- 
memoto  et al., 1994). 
Our  results a lso demonst ra te  that f ibroblast  and hemato-  
poiet ic cells are not equ iva lent  for t rans format ion  by BCR-  
ABL. Whi le the BCR-ABL  Y793F  and Y177F  mutants  are 
unable  to t ransform f ibroblast  cells, they can readi ly  trans- 
form bone marrow cel ls in vitro and demonst ra te  a highly 
mal ignant  phenotype  in vivo. In addit ion, the BCR-ABL  
SH2 domain  appears  to t ransmit  a critical s ignal  for malig- 
nant  growth in vivo. Recently,  Songyang et al. (1995) have 
demonst ra ted  that  cytop lasmic  tyros ine k inase domains  
se lect  pept ides with s imilar sequences  as their  adjo in ing 
SH2 domains.  This  suggests  that the SH2 domain  may 
funct ion to make the BCR-ABL  tyros ine k inase s ignal  
more effect ive for t ransformat ion.  
Overexpress ion  of  c -MYC can ef fect ively rescue the 
SH2 domain mutant  of  BCR-ABL  for f ibroblast  cell trans-  
format ion (Afar et al., 1994). The  cell cycle regulatory  pro- 
tein cyclin D1 has also been recent ly  shown to rescue the 
BCR-ABL  SH2 mutant  for f ibroblast  t rans format ion  and 
in vivo tumor igenes is  (Afar et al., 1995). These  results 
suggest  that a number  of cell cycle components  including 
MYC and cyclin D1 act downst ream of  an SH2-dependent  
s ignal ing pathway for BCR-ABL  mal ignant  t ransforma-  
tion. BCR-ABL  mutants  that are  impaired for  t ransforma-  
tion or in vivo mal ignant  growth thus prov ide us with a 
useful  tool to examine  s ignal ing.  The  se lect ive comple-  
mentat ion of d i f ferent  BCR-ABL  mutants  by s ignal ing mol- 
ecu les  should  permit  us to def ine genet ica l ly  pathways 
involved in BCR-ABL  hematopo ie t i c  t ransformat ion.  
Experimental Procedures 
Plasmid Constructions and Preparation of Viral Stocks 
The pSRaMSVtkneo vector (Muller et al., 1991) was used to produce 
helper-free retroviral stocks by transient overexpression in 293 T cells 
(Pear et al., 1993; Afar et al., 1994). Cloning of the different P185 
BCR-ABL mutants into the retroviral vector has been previously de- 
scribed (Afar et al., 1994; Pendergast et al., 1993b). To generate combi- 
nations of double- and triple-point mutants of P185 BC R-ABL, we took 
advantage of a unique Kpnl site located at position (2054) within P185 
BCR-ABL. The SHC cDNA was cloned into the pSRaMSVtk vector at 
the upstream EcoRI site. Different forms of BCR-ABL were cloned at 
the Notl restriction site downstream of the thymidylate kinase pro- 
moter. Viral stocks were quantitated by acute infection of 1 x 10 s 
Rat1 fibroblast cells. At 48 hr postin fection, BCR-ABL genome transfer 
was assesed by expression of BCR-ABL proteins. Viral stocks were 
normalized to give approximately equivalent protein expression for 
the various BCR-ABL mutants. 
Growth Factor Independence Assays and Soft Agar Assays 
Rat1 fibroblast ransformation by BCR-ABL mutants was quantitated 
via a soft agar transformation assay as previously described (Lugo et 
al., 1990). Growth factor independence assays of I L-7-dependent clone 
H cells (Young et al., 1991) or GM-CSF-dependent DAGM myeloid 
cells (Rennick et al., 1987) were performed as previously described 
(Pendergast et al., 1993a). In brief, 1 x 106 hematopoietic ells or 
1 x 10 s fibroblast cells were infected with retroviruses encoding the 
indicated BCR-ABL forms. Infections were performed for 3 hr at 37°C 
with 3.0 ml of virus stock. At 2 days postinfection, 5 x 10" fibroblast 
cells per 6 cm dish were plated, in duplicate, onto soft agar containing 
20% serum. After 3 weeks of growth in agar, colonies larger than 0.75 
mm in size were scored as positive. Following infection, hematopoietic 
cell lines were grown in appropriate growth factor for 2 days. Cells 
were then washed twice in media to remove exogenous growth factors 
and plated in 96-well dishes at a density of 1 x 104 cells/well. At 2 
weeks postinfection, wells that demonstrated an outgrowth of factor- 
independent cells were scored positive. 
Western Blotting and Immunoprecipitations 
Expression of BCR-ABL mutants and analysis of tyrosine-phosphory- 
lated proteins was done on 15 ~g of total cell extracts from Rat1 fibro- 
blast cells or from transformed hematopoietic ells. Anti-ABL Western 
blots were probed with 21-24 monoclonal antibody (Oncogene Sci- 
ences). Anti-phosphotyrosine blots were probed with 4G10 mono- 
clonal antibody (U BI). SHC and GRB2 antibodies were purchased from 
Transduction Labs. For immunoprecipitation f BCR-ABL protein, 5 x 
106 transformed high density bone marrow cells were lysed in 0.5 ml 
of lysis buffer (10 mM HEPES {pH 7.4], 150 mM NaCI, 10% glycerol, 
1 mM NaVO4, and 1 mM PMSF). For immunoprecipitation of SHC 
proteins, 5 x 108 parental DAGM cells or cells that had been rendered 
growth factor independent by various BCR-ABL mutants were lysed 
in lysis buffer. Lysates were clarified by centrifugation for 15 rain at 
14,000 x g in a refrigerated microcentrifuge. Lysates were incubated 
with pEX5, a carboxy-terminal, anti-ABL polyclonal antibody (Konopka 
et al., 1984) or with 1.5 ~g of affinity-purified polyclonal SHC antibody 
for 2-4 hr on ice. Immune complexes were collected by the addition 
of protein A-Sepharose beads for 2 hr with constant shaking at 4°C, 
followed by washing 3-4 times in lysis buffer. 
Murine Bone Marrow Transformation Assay 
Fresh bone marrow from the tibias and femurs of 3- to 4-week-old 
BALB/c mice was infected with matched retroviral stocks of different 
BCR-ABL mutants and plated at a density of 5 x 106 cells per 6 cm 
dish as previously described (McLaughlin et al., 1989). The number 
of nonadherent cells was counted 21 days post infection. A plate was 
scored positive if the cell count exceeded 1 x 106 cells/ml. 
Tumor Challenges 
Cell lines were generated from bone marrow cells transformed in vitro 
by wild type or BCR-ABL mutants. Cell lines were selected that could 
grow in the absence of a stromal feeder layer. Transformed lymphoid 
cells (1 x 106) were injected subcutaneously per site into the flanks 
of nonirradiated CB-17 scid/scid mice. Immune-deficient CB-17 scid/ 
scid mice were bred and maintained in a laminar flow tower in a defined 
flora colony. Mice were observed for the growth of tumors at the local 
site site of injection. Mice that developed tumors (>1 cm in diameter) 
were autopsied and examined for the signs of metastatic growth of 
transformed bone marrow cells. 
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